Skip to main content
SpringerLink
Log in

Traitement des formes de mauvais pronostic

  • Chapter
Book cover Cancer du testicule

Part of the book series: Monographies en urologie ((MONOGRAPHIES))

  • 223 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Samuels ML, Johnson DE, Holoye PY (1975) Continuous intravenous bleomycin (NSC-125066) therapy with vinblastine (NSC-49842) in stage III testicular neoplasia. Cancer Chemother Rep 59: 563–70

    PubMed  CAS  Google Scholar 

  2. Einhorn LH (1990) Treatment of testicular cancer: a new and improved model. J Clin Oncol 8: 1777–81

    PubMed  CAS  Google Scholar 

  3. IGCCC Group (1997) International germ cell consensus classification: A prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15: 594–603

    Google Scholar 

  4. Droz JP, Kramar A, Rey A (1992) Prognostic factors in metastatic disease. Semin Oncol 19: 181–9

    PubMed  CAS  Google Scholar 

  5. Williams SD, Birch R, Einhorn LH et al. (1987) Treatment of disseminated germ-cell tumors with cisplatin, bleomycin and either vinblastine or etoposide. N Engl J Med 316: 1435–40

    PubMed  CAS  Google Scholar 

  6. Ozols RF, Ihde DC, Linehan WM et al. (1988) A randomized trial of standard chemotherapy v. a high dose chemotherapy regimen in the treatment of poor prognosis metastatic non-seminomatous germ-cell tumours. J Clin Oncol 6: 1031–40

    PubMed  CAS  Google Scholar 

  7. Nichols CR, Williams S, Loehrer PJ et al. (1991) Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: A Southeastern cancer study group and Southwest oncology group protocol. J Clin Oncol 9: 1163–72

    PubMed  CAS  Google Scholar 

  8. Wheeler BM, Loehrer PJ, Williams SD et al. (1986) Ifosfamide in refractory male germ cell tumours. J Clin Oncol 4: 28–34

    PubMed  CAS  Google Scholar 

  9. Nichols CR, Catalano PJ, Crawford ED et al. (1998) Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, SouthWest Oncology Group, and Cancer And Leukemia Group B study. J Clin Oncol 4: 1287–93

    Google Scholar 

  10. Bosl GJ, Geller NL, Vogelzang NJ et al. (1987) Alternating cycles of etoposide plus cisplatin and VAB-6 in the treatment of poor-risk patients with germ cell tumors. J Clin Oncol 5: 436–40

    PubMed  CAS  Google Scholar 

  11. Bower M, Newlands ES, Holden L et al. (1997) Treatment of men with metastatic nonseminomatous germ cell tumours with cyclical POMB/ACE chemotherapy. Ann Oncol 8: 477–83

    Article  PubMed  CAS  Google Scholar 

  12. Droz JP, Culine S, Bouzy J et al. (2001) Preliminary results of a randomized trial comparing bleomycin, etoposide, cisplatin (BEP) and cyclophosphamide, doxorubicin, cisplatin/vinblastin, bleomycin (CISCA/VB) for patients with intermediate and poor-risk metastatic non-seminomatous germ-cell tumors. Proc Am Soc Clin Oncol 20: 204

    Google Scholar 

  13. Chong CD, Logothetis CJ, von Eschenbach AC et al. (1988) Successful treatment of pure endodermal sinus tumors in adult men. J Clin Oncol 6: 303–7

    PubMed  CAS  Google Scholar 

  14. Kaye SB, Mead GM, Fossa SD et al. (1998) Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumour: a Randomized Medical Research Council / European Organization for Research and Treatment of Cancer Study. J Clin Oncol 2: 692–701

    Google Scholar 

  15. Droz JP, Culine S, Biron P et al. (1996) High-dose chemotherapy in germ-cell tumors. Ann Oncol 7: 997–1003

    PubMed  CAS  Google Scholar 

  16. Motzer RJ, Mazumdar M, Gulati SC et al. (1993) Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Natl Cancer Inst 85: 1828–35

    PubMed  CAS  Google Scholar 

  17. Motzer RJ, Mazumdar M, Bajorin DF et al. (1997) High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Clin Oncol 15: 2546–52

    PubMed  CAS  Google Scholar 

  18. Droz JP, Pico, Biron P et al. (1992) No evidence of a benefit of early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor-risk non-seminomatous germ cell tumours: preliminary results of a randomized trial. Proc Am Soc Clin Oncol 11: 197

    Google Scholar 

  19. Schmoll HJ, Kollmannsberger C, Metzner B et al. (2003) Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. J Clin Oncol 21: 4083–91

    Article  PubMed  CAS  Google Scholar 

  20. Motzer RJ, Bajorin DF, Schwartz LH et al. (1994) Phase II trial of Paclitaxel shows antitumour activity in patients with previously treated germ cell tumours. J Clin Oncol 12: 2277–83

    PubMed  CAS  Google Scholar 

  21. Bokemeyer C, Gerl A, Schoffski P et al. (1999) Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer. J Clin Oncol 17: 512–5

    PubMed  CAS  Google Scholar 

  22. Dunn TA, Schmoll HJ, Grunwald V et al. (1997) Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell-lines. Investigational New Drugs 15: 109–14

    PubMed  CAS  Google Scholar 

  23. Coogan CL, Hejase MJ, Wahle GR et al. (1996) Nerve sparing post-chemotherapy retroperitoneal lymph node dissection for advanced testicular cancer. J Urol 156: 1656–58

    PubMed  CAS  Google Scholar 

  24. Toner GC, Panicek DM, Heelan RT et al. (1990) Adjunctive surgery after chemotherapy for non seminomatous germ cell tumors: recommendations for patient selection. J Clin Oncol 10: 1683–94

    Google Scholar 

  25. Wood DP Jr, Herr HW, Heller G et al. (1992) Distribution of retroperitoneal metastases after chemotherapy in patients with nonseminomatous germ cell tumors. J Urol 148: 1812–5

    PubMed  Google Scholar 

  26. Aprikian AG, Herr HW, Bajorin DF et al. (1994) Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors. Cancer 74: 1329–34

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service d’oncologie médicale du Pr Droz, Centre Léon-Bérard, 28, rue Laennec, 69373, Lyon Cedex 08

    A. Fléchon & J.-P. Droz

Authors
  1. A. Fléchon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J.-P. Droz
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag France, Paris

About this chapter

Cite this chapter

Fléchon, A., Droz, JP. (2006). Traitement des formes de mauvais pronostic. In: Cancer du testicule. Monographies en urologie. Springer, Paris. https://doi.org/10.1007/2-287-31232-3_13

Download citation

  • DOI: https://doi.org/10.1007/2-287-31232-3_13

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-21243-7

  • Online ISBN: 978-2-287-31232-8

Publish with us

Policies and ethics

Search

Navigation